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Abstract
Background: Chronic kidney disease (CKD) affects drug elimination and patients with CKD require appropriate
adjustment of renally cleared medications to ensure safe and effective pharmacotherapy. The main objective of this
study was to determine the extent of potentially inappropriate prescribing (PIP; defined as the use of a
contraindicated medication or inappropriately high dose according to the kidney function) of renally-cleared
medications commonly prescribed in Australian primary care, based on two measures of kidney function. A
secondary aim was to assess agreement between the two measures.
Methods: Retrospective analysis of routinely collected de-identified Australian general practice patient data (NPS
MedicineWise MedicineInsight from January 1, 2013, to June 1, 2016; collected from 329 general practices). All
adults (aged ≥18 years) with CKD presenting to general practices across Australia were included in the analysis.
Patients were considered to have CKD if they had two or more estimated glomerular filtration rate (eGFR) recorded
values < 60 mL/min/1.73m2, and/or two urinary albumin/creatinine ratios ≥3.5 mg/mmol in females (≥2.5 mg/mmol
in males) at least 90 days apart. PIP was assessed for 49 commonly prescribed medications using the Cockcroft-
Gault (CG) equation/eGFR as per the instructions in the Australian Medicines Handbook.
Results: A total of 48,731 patients met the Kidney Health Australia (KHA) definition for CKD and had prescriptions
recorded within 90 days of measuring serum creatinine (SCr)/estimated glomerular filtration rate (eGFR). Overall, 28,
729 patients were prescribed one or more of the 49 medications of interest. Approximately 35% (n = 9926) of these
patients had at least one PIP based on either the Cockcroft-Gault (CG) equation or eGFR (CKD-EPI; CKD-
Epidemiology Collaboration Equation). There was good agreement between CG and eGFR while determining the
appropriateness of medications, with approximately 97% of the medications classified as appropriate by eGFR also
being considered appropriate by the CG equation.
Conclusion: This study highlights that PIP commonly occurs in primary care patients with CKD and the need for
further research to understand why and how this can be minimised. The findings also show that the eGFR provides
clinicians a potential alternative to the CG formula when estimating kidney function to guide drug appropriateness
and dosing.
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Background
The prevalence of chronic kidney disease (CKD) is
rapidly increasing worldwide, alongside its complications
[1–3]. Most people with CKD are prescribed a multitude
of drugs to treat the underlying cause of kidney disease,
or its numerous complications and comorbidities [2, 3].
The reduction in kidney function requires adaptation of
treatment regimens as the pharmacokinetics and
pharmacodynamics of many drugs are altered. Dosing
errors are common in CKD and can cause adverse ef-
fects and poor outcomes [2].
Previous studies have reported potentially inappropri-
ate prescribing (PIP) of medications in CKD (defined as
the use of a contraindicated medication or inappropri-
ately high dose according to the kidney function) ran-
ging from 13 to 80%, with most of the medications
being initiated in the community setting [2, 4]. In
Australia, the prevalence of PIP in patients with renal
impairment in primary care has received less attention.
One study reported that 32% of patients with CKD were
receiving PIP at the time of admission to hospital [2].
The automated reporting of estimated glomerular
filtration rate (eGFR) calculated from the modification
of diet in renal disease (MDRD) or CKD epidemiology
collaboration equation (CKD-EPI) is now routinely pro-
vided by laboratories whenever a serum creatinine (SCr)
value is measured, as a tool to enhance the identification
and classification of CKD [5]. Most of the drug dosing
studies to date, however, have used the Cockcroft-Gault
(CG) equation to estimate kidney function as creatinine
clearance (CrCl), which includes a weight component
[6]. While the CG equation is still the preferred equation
for drug dosage adjustment by most drug information
sources, it is cumbersome to calculate in the busy con-
text of a general practice consultation.
Given this background, the main objective of this
study was to determine the extent of PIP of renally-
cleared medications commonly prescribed in Australian
primary care, based on two separate estimates of kidney
function (CG and CKD-EPI).
Methods
This retrospective study included data collected by
MedicineInsight, developed and managed by NPS Medi-
cineWise. MedicineInsight is a large-scale national data
program in Australia to extract and collate longitudinal,
whole-of-practice data from the clinical information
systems of consenting general practices. De-identified
patient data collected include demographics, encounters
(not including progress notes), diagnoses, prescriptions
and pathology tests. As of July 2017, MedicineInsight
had recruited 650 general practices with data pertaining
to 3.6 million patients [3, 7, 8]. The Institutional Human
Research Ethics Committee approved the study
(H0015651). The study is reported as per the reporting
of studies conducted using observational routinely col-
lected health data statement for pharmacoepidemiology
(RECORD-PE) guideline [9].
We used MedicineInsight data from January 1, 2013 to
June 1, 2016, collected from 329 general practices dis-
tributed across Australia. Patients were initially included
if at the time of data extract they were aged at least 18
years, met the Royal Australian College of General Prac-
tice (RACGP) definition of an “active” patient (attended
at least three times at the same general practice within a
two-year period), and could be diagnosed with CKD
based on their laboratory pathology results (having two
or more eGFR values less than 60mL/min/1.73m2, and/
or two urinary albumin/creatinine ratios (ACR) ≥ 3.5
mg/mmol in females or ≥ 2.5 mg/mmol in males, at least
90 days apart) [1].
A total of 60,433 patients out of 1.48 million (approxi-
mately 4%) in the dataset met the Kidney Health
Australia (KHA) guidelines for the diagnosis of CKD [1].
For assessing the quality use of medicines (QUM) in kid-
ney disease we included a total of 49 medications, which
were part of a national campaign to improve prescribing
in the elderly in 2012 [10]. The list was adapted to in-
clude some medications that were commonly associated
with PIP in other research [2]. Patients’ medications
were included if they were prescribed within 90 days fol-
lowing the pathology test. PIP was defined as prescribing
of a medication that is contraindicated or at an inappro-
priately high dose according to the patient’s kidney func-
tion. Appropriateness was assessed using the Australian
Medicines Handbook (AMH) [11]. Only medications
that had clear recommendations were included in the
analysis. Medications with ambiguous dosage adjustment
recommendations were excluded from the analysis e.g.
Ramipril- “In patients with renal impairment, elderly or
taking a diuretic, initially 2.5mg once daily” [11].
Additionally, medications that were available in combin-
ation were assessed for PIP separately. For example;
metformin and sitagliptin were assessed for PIP and
reported separately. Examples of drugs and recommen-
dations extracted from the AMH are presented in
Additional file 1. The complete list of medications and
recommendations is available on request.
Statistical analysis
Descriptive statistics were used to describe the data, with
mean ± standard deviation (SD) and percentages/propor-
tions. PIP of medications, i.e. both potentially contrain-
dicated and inappropriately dosed medications, were
compared for appropriateness between the CKD-EPI
and CG equations (patients with weight and height doc-
umented). The level of agreement in evaluating appro-
priateness between the equations was calculated by
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Cohen’s kappa and Gwet first-order agreement coeffi-
cient (AC1) [12]. For Cohen’s Kappa, a value of < 0.6
was defined as poor agreement, 0.6–0.8 as moderate
agreement, 0.8 to < 0.9 as good agreement and ≥ 0.9 as
excellent agreement. Gwet AC1 provides an alternative
in circumstances where Kappa is low despite a high level
of agreement and has been shown to provide a more
stable inter-rater reliability coefficient than Cohen’s
kappa [12]. All data cleaning and manipulation, and stat-
istical analyses were completed using the statistical and
graphical computing language of R [13]. A p value of <
0.05 was considered statistically significant.
Results
A total of 48,731 patients met the KHA definition for
CKD and had prescriptions recorded within 90 days of
measuring kidney function. Overall, 28,729 patients were
prescribed one or more of the 49 medications of interest
(Table 1). Over 90% of these patients (n = 25,975) were ≥
65 years of age and 55.7% (n = 15,993) were female. The
mean (SD) number of medications and medical condi-
tions were 8.4 (3.8) and 2.2 (1.0), respectively. Over 80%
(n = 23,998) of the patients had hypertension, while over
40% had diabetes and/cardiovascular disease (n = 13,292
and 13,611, respectively). Among the 28,729 patients, al-
most all 98.5% (n = 28,315) were in Stage 3, 4 and 5
CKD. The most common drug class prescribed across
the study sample were agents pertaining to the renin-
angiotensin system (RAS).
Potentially inappropriate prescribing
A breakdown of PIP across the different stages of CKD
is provided in Fig. 1. Overall, 35% (n = 9926) patients
had at least one PIP based on either CG CrCl or eGFR.
Approximately 6.5% (n = 1866) and 1.8% (n = 505) were
prescribed 2 and 3 or more potentially inappropriate
medications (PIMs), respectively (Table 2). A total of
1171 patients (4.1%) were prescribed both a contraindi-
cated medication and a medication at an inappropriate
dose as per their kidney function.
Analgesics, prescribed across 7.2% patients (n = 2082),
were the most frequent inappropriate class of medica-
tion [n = 1536 (73.8% of patients prescribed the drugs)]
followed by medications for diabetes [prescribed n =
8730 (30.4%); PIP n = 3384 (44.1%)] and beta-blockers
[prescribed n = 4832 (16.8%); PIP n = 1849 (38.2%)]. Vil-
dagliptin [prescribed n = 355 (1.2%); PIP n = 274 (77.2%)]
followed by fenofibrate [prescribed n = 1939 (6.7%); PIP
n = 1346 (69.4%)] were the most commonly prescribed
medications at an inappropriate dose, whilst dapagliflo-
zin [prescribed n = 296 (1%); PIP n = 245 (82.8%)]
followed by alendronate [prescribed n = 791(2.8%); PIP
n = 251 (31.7%)] had the highest rates of use when con-
traindicated either by CG CrCl or eGFR (Table 3).
Codeine, glibenclamide and glimepiride were associated
with PIP in all patients prescribed these drugs, as the
AMH recommends their avoidance in renal impairment,
and these were excluded from the final analysis.
Agreement between eGFR (CKD-EPI) and CrCl (CG
equation)
Overall, there was good agreement between CG CrCl
and eGFR (CKD-EPI) when determining the appropri-
ateness of medications. Approximately 97% of medica-
tions that were classified as appropriate by eGFR were
considered to be appropriate by the CG equation, while
88.1 and 61.1% of the medications considered to be con-
traindicated and inappropriately dosed by eGFR, were
considered to be contraindicated and inappropriately
dosed by the CG equation, respectively (Fig. 2). The top
Table 1 Characteristics of the study sample (n = 28,729)
Demographics Number (%)
Age (years)
20–29 6 (0.02)
30–39 61 (0.21)
40–49 257 (0.89)
50–59 1039 (3.62)
60–69 4234 (14.74)
70–79 10,219 (35.57)
80–89 10,434 (36.32)
90+ 2479 (8.63)
Male Gender 12,736 (44.3)
CKD Risk Factors
Hypertension 23,998 (83.2)
CVD 13,611 (47.4)
Diabetes 13,292 (46.3)
Number of medications [Mean (SD)] 8.42 (3.75)
Top 5 medications categorised according to the ATC groups
Agents acting on the renin-angiotensin system 20,391 (71.0)
Analgesics 16,084 (56.0)
Drugs for acid-related disorders 15,861 (55.2)
Antithrombotic drugs 11,691 (40.7)
Diuretics 10,965 (38.2)
Stages of CKD
Stage 1≥ 90 mL/min/1.73m2 27 (0.1)
Stage 2 60–89 mL/min/1.73m2 387 (6.8)
Stage 3a 45–59 mL/min/1.73m2 18,553 (64.6)
Stage 3b 30–44mL/min/1.73m2 7539 (26.2)
Stage 4 15–29 mL/min/1.73m2 1955 (6.8)
Stage 5 < 15 mL/min/1.73m2 268 (0.9)
CVD Cardiovascular disease, ATC Anatomical Therapeutic Chemical
classification system
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Fig. 1 Potential inappropriate prescribing as per CKD stage
Table 2 Potentially inappropriate medications (PIMs) in the study sample
Characteristic Number (%)
PIMs
0 18,803 (65.4)
1 7555 (26.3)
2 1866 (6.5)
≥ 3 505 (1.8)
Patients with potentially inappropriate dose 7312 (25.5)
0 21,417 (74.5)
1 5983 (20.8)
2 1143 (4.0)
≥ 3 186 (0.6)
Patients with potentially contraindicated medication 3786 (13.2)
0 24,943 (86.8)
1 3494 (12.2)
2 265 (0.9)
≥ 3 27 (0.1)
Patients with both potentially inappropriate dose and contraindicated medication 1171 (4.1)
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Table 3 Medications with potentially inappropriate prescribing
Medications with
potentially inappropriate
dose
Patients
prescribed N
(%)
Patients with
inappropriately high
dose drug
N (%)
Medications potentially
contraindicated
Patients
prescribed N
(%)
Patients with potentially
contraindicated medication N
(%)
Antidiabetic Medications Antidiabetic Medications
Vildagliptin 355 (1.2) 274 (77.2) Dapagliflozin 296 (1.0) 245 (82.8)
Saxagliptin 205 (0.7) 117 (57.1) Acarbose 81 (0.3) 12 (14.8)
Sitagliptin 1534 (5.3) 742 (48.4) Exenatide 313 (1.1) 18 (5.8)
Metformin 8046 (28.0) 2885 (35.9) Metformin 8046 (28.0) 37 (0.5)
Alogliptin 17 (0.1) 5 (29.4) Anticoagulant Medications
Lipid Lowering Medications Rivaroxaban 1230 (4.3) 99 (8.0)
Fenofibrate 1939 (6.7) 1346 (69.4) Dabigatran 492 (1.7) 34 (6.9)
Rosuvastatin 8529 (29.7) 525 (6.2) Apixaban 938 (3.3) 40 (4.3)
Antihypertensive Medications Cardiovascular Medications
Atenolol 4832 (16.8) 1849 (38.3) Moxonidine 1675 (5.8) 447 (26.7)
Moxonidine 1675 (5.8) 43 (2.6) Spironolactone 3050 (10.6) 665 (21.8)
Antiarrhythmics Bisphosphonates
Digoxin 2567 (8.9) 24 (0.9) Alendronate 791 (2.8) 251 (31.7)
Anticoagulant Medications Risedronate 619 (2.2) 118 (19.1)
Rivaroxaban 1230 (4.3) 237 (19.3) Others
Dabigatran 492 (1.7) 39 (7.9) Teriparatide 7 (0.0) 2 (28.6)
Bisphosphonates Strontium 205 (0.7) 43 (21.0)
Clodronate 10 (0.03) 5 (50) Dextropropoxyphene 105 (0.4) 33 (31.4)
Zoledronate 24 (0.1) 1 (4.2) Pramipexole 523 (1.8) 100 (19.1)
Antihistamines Probenecid 115 (0.4) 1 (0.9)
Nizatidine 283 (1.0) 170 (60.1)
Cimetidine 15 (0.1) 3 (20.0)
Cetirizine 261 (0.9) 50 (19.2)
Psychotropic Medications
Paliperidone 6 (0.02) 4 (66.7)
Desvenlafaxine 572 (2.0) 70 (12.2)
Duloxetine 846 (2.9) 87 (10.3)
Venlafaxine 1050 (3.7) 47 (4.5)
Varenicline 150 (0.5) 6 (4.0)
Neurological Medications
Tramadol 571 (2) 67 (11.7)
Gabapentin 341 (1.2) 30 (8.8)
Levetiracetam 179 (0.6) 9 (5)
Pregabalin 4642 (16.2) 190 (4.1)
Pramipexole 523 (1.8) 3 (0.6)
Others
Tolterodine 20 (0.1) 2 (10.0)
Solifenacin 458 (1.6) 21 (4.6)
Codeine, Glibenclamide and Glimepiride were prescribed inappropriately in all patients and is not presented in the table; Combination medications were assessed for
PIP separately
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3 medications in disagreement between the two equa-
tions are presented in Table 4. A total of 40 medications
from the 49 of interest, that had been rated PIP at least
once, were tested for inter-rater agreement. Twenty-
seven medications scored a Cohen’s kappa value < 0.6
whereas Gwet’s AC1 scores were between 0.75–1.0.
Discussion
The results demonstrate that Australian general practice
patients with CKD are frequently prescribed PIP. Ap-
proximately 35% of the patients were prescribed at least
one PIP. The findings have corroborated the high rate of
potentially contraindicated medications and inappropri-
ate dosing found in international studies, including a
systematic review that reported rates of PIP between 13
to 80% [2, 4]. These results highlight the need for further
research to determine the reasons, leading to interven-
tions to optimise prescribing in patients with CKD in
general practice.
The extent of PIP in our study and the previous litera-
ture highlights the complexity of prescribing in CKD
and could be due to the contribution of several factors.
Firstly, in Australia there is a lack of up-to-date access-
ible guidelines on drug dose adjustments in patients with
impaired kidney function. Another important aspect to
consider is the inconsistencies with dosage adjustment
recommendations between different drug information
sources, as well as the product information of different
brands of the same drug [14, 15]. It is important to note
that most drug information sources provide dosage ad-
justment based on the CG equation rather than eGFR
formulae (MDRD/CKD-EPI), whilst eGFR (especially
CKD-EPI) based formulae have been found to be the
most accurate indicator of kidney function [16]. Sec-
ondly, many of the recommendations based on the CG
equation are questionable due to the variability in cre-
atinine assays at the time and were prior to SCr being
isotope dilution mass spectrometry (IDMS) standardised.
CG-estimated GFR results are 5–10% higher using the
standardised SCr measurements compared to the non-
standardised SCr and relying on the CG equation could
lead to unintended consequences, including insufficient
Fig. 2 Agreement of equations in determining PIP
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dose adjustments for kidney function [17, 18]. However,
the clinical significance of this theoretical issue is un-
known and needs to be evaluated further. Hence, current
recommendations include using either CG equation due
to considerable experience with the formula even if it is
based on creatinine assays not in use. It is also appropri-
ate to use eGFR formula (CKD-EPI) for most drugs
without body surface area (BSA) adjustment [1, 16].
The nature of the electronic health record (eHR) may
also be a potential factor for PIP. The current eHR may
not alert prescribers to appropriately adjust dosages of
medications cleared by the kidney unless the patient has
CKD recorded as a diagnosis. Only 20% of the patients
included had a formal diagnosis of CKD documented
whilst all patients had laboratory evidence of CKD and
this lack of coding of CKD as a condition may have had
a role in the PIP findings [7, 8]. Whilst the overall preva-
lence of CKD in our study was comparable to the previ-
ous Australian Bureau of Statistics (ABS) results, the
prevalence is lower than previous International litera-
ture. The potential reasons for the lower prevalence have
been described in detail elsewhere [3]. It is important to
note that in many older people with stable eGFR values
from 45 to 59mL/min/1.73 m2 debate on the definition
and staging of CKD exists as to whether CKD may be
over diagnosed. However, these values are a sign of im-
paired kidney function that could affect the clearance of
drugs. Hence, it is essential to consider renal function
when prescribing renally-cleared medications as the PIP
may lead to adverse outcomes.
The agreement between the two equations (CG and
CKD-EPI) was excellent, with 97% of the medications
rated as appropriate by eGFR being also rated as appro-
priate by the CG equation. Previous studies comparing
drug doses derived from eGFR equations and CG have
commonly reported discordance rates between 10 and
40% [19, 20]. These results highlight that for most pa-
tients with renal impairment the same recommendation
between eGFR or CG estimate can be used, with any dif-
ference in the kidney function estimate unlikely to lead
to an overdose [21] However, it is important for some
drugs, and the potential clinical significance of disagree-
ment between eGFR and CG-based dosing regimens
should be minimised by using sound clinical judgment
[22]. For example, our study showed that rivaroxaban
was one of the medications associated with disagreement
between the equations. A recent study by Szummer
et al. comparing eGFR (CKD-EPI, MDRD) and the CG
equation suggested that when prescribing one of the
novel oral anticoagulants, the CG equation should be
considered, as it provides a more conservative approach
for avoiding drug exposure and reducing the risk of
bleeding [23]. A similar approach is recommended by
the National Kidney Disease Education Program
(NKDEP) in the USA and by KHA, where eGFR can be
used for dosage adjustment for most drugs (without
BSA adjustment) except for drugs with a narrow thera-
peutic index (e.g. anticoagulants), where conservative
kidney function estimates and corresponding doses are
recommended, particularly if therapeutic drug monitor-
ing is not readily available [16].
Most of the medications with PIP were consistent with
previous studies [2]. Antidiabetic agents and cardiovas-
cular drugs were commonly associated with PIP, which
is not surprising given that both diabetes and CVD often
co-exist with CKD. Almost half of our patients were be-
ing treated for diabetes and CVD. A large proportion of
oral antidiabetic agents are excreted by the kidney [11].
It is likely that concomitant chronic diseases complicate
and confound the treatment of each other. These medi-
cations are adjusted frequently in response to cardiac,
renal or electrolyte disturbances, and are at a higher risk
of being potentially inappropriate.
It is important to note that for some medications com-
monly prescribed in the study (for example, atenolol)
clinical markers, such as heart rate and blood pressure,
are often more important than kidney function in guid-
ing dosage adjustment. Additionally, some medications
do not have adequate published data in patients with
renal impairment and may have been conservatively rec-
ommended as to be avoided rather than having an in-
creased potential for toxic effects [11].
Our study also showed that PIP was common across
all stages of CKD. Although stages 1, 2 and 3a CKD
Table 4 Top 3 medications considered in disagreement
between CG CrCl and eGFR (CKD-EPI)
CKD-EPI eGFR CG Equation Medication N (%)
Appropriate Contraindicated Spironolactone 229 (27.8)
Alendronate 186 (22.5)
Risedronate 105 (12.7)
Inappropriate dose Atenolol 501 (32.3)
Metformin 272 (17.5)
Sitagliptin 169 (10.9)
Contraindicated Appropriate Moxonidine 270 (30.5)
Spironolactone 241 (27.3)
Dapagliflozin 177 (20)
Inappropriate dose Moxonidine 7 (46.7)
Metformin 4 (26.7)
Rivaroxaban 4 (26.7)
Inappropriate dose Appropriate Metformin 1812 (35.5)
Fenofibrate 915 (17.9)
Atenolol 675 (13.2)
Contraindicated Rivaroxaban 13 (52.0)
Metformin 12 (48.0)
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seldom impact on the prescribing of renally cleared
medications, several common medications such as met-
formin, gliptins and SGLT2 inhibitors do have specific
recommendations in patients with early stages of CKD.
Previous studies in patients with advanced CKD have
shown contrasting results. Some studies have reported
that in patients with advanced CKD the likelihood of
PIP is less due to more vigilant monitoring and nephrol-
ogy consultations, while other studies have shown an
increased number of problems [24–26]. Further research
to understand the phenomenon of PIP in general prac-
tice is needed, possibly leading to the design of interven-
tions to optimise medication prescribing in patients with
CKD. Optimal use of current eHR systems to flag
renally-impaired patients so that PIP is identified is likely
to be part of an intervention.
The major strength of the current study is that it
assessed prescriptions in primary care in a large cohort
of patients. Previous Australian studies of inappropriate
drug prescriptions in CKD have focussed on older
people in the community and aged care settings, or
when patients were admitted to the hospital [4]. How-
ever, the study does have some limitations. Prescribers
may not always have had pathology results available at
the time of prescribing. However, we evaluated the ex-
tent of PIP for medications prescribed within 90 days of
the availability of a kidney function assessment. We did
not examine any adverse clinical outcomes associated
with PIP. Additionally, prescribing may be appropriate at
times with benefits outweighing the additional risks or if
no safer alternatives are available.
Conclusion
Our study highlights that PIP is common in Austra-
lian general practice, underlining the complexity of
prescribing for patients with CKD. Understanding sit-
uations where prescribing is truly inappropriate would
assist in the design of interventions to improve safe
medication prescribing in patients with CKD. Our
study also shows that although CrCl using the CG
formula has been the most common method of esti-
mating kidney function for drug dosing purposes for
over 40 years, the widespread availability and extensive
clinical use of eGFR now provides clinicians with a
potential alternative. However, careful consideration
of the risk-benefit ratio of individual drugs and doses
within each patient is warranted.
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